The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBowleven Regulatory News (BLVN)

Share Price Information for Bowleven (BLVN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.15
Ask: 0.25
Change: 0.00 (0.00%)
Spread: 0.10 (66.667%)
Open: 0.20
High: 0.20
Low: 0.175
Prev. Close: 0.20
BLVN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights and Share Capital

28 Feb 2017 17:00

RNS Number : 1086Y
BowLeven Plc
28 February 2017
 

 

 

 

 

 

 

28 February 2017

 

Bowleven plc ('Bowleven')

 

Total Voting Rights and Share Capital

 

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company announces that as at 28 February 2017, the Company's issued share capital consists of 328,520,570 ordinary shares with a nominal value of 10 pence each ("Shares"). Bowleven holds 7,807,281 Shares in treasury. Therefore, the total number of voting rights in the share capital of the Company is 320,713,289 (one vote per Share).

 

The above figure of 320,713,289 may be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules of the Financial Conduct Authority.

 

Block Admission Six Monthly Return

This Block Admission Six Monthly Return is intended to comply with the requirements of AIM Rule 29 and Schedule Six.

 

Name of company:

BOWLEVEN PLC

Name of scheme:

1) BOWLEVEN PLC APPROVED CSOP SCHEME (WITH UNAPPROVED SCHEDULE)

2) BOWLEVEN PLC SCHEDULE 4 CSOP SCHEME (WITH UNAPPROVED SCHEDULE)

Period of return:

From:

1 SEPTEMBER 2016

To:

28 FEBRUARY 2017

Balance of unallotted securities under scheme(s) from previous return:

186,813 ORDINARY SHARES

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

276,409

Less: Number of securities issued/allotted under scheme(s) during period:

463,222

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

NIL

Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission:

1,000,000 ORDINARY SHARES

1 MARCH 2011

Total number of shares in issue at the end of the period:

328,520,570

     

 

 

ENQUIRIES

For further information, please contact:

Bowleven plc

Kevin Hart, Chief Executive 00 44 131 524 5678

Kerry Crawford, Finance Director

 

Brunswick Group LLP

Patrick Handley 00 44 207 404 5959

Will Rowberry

 

Cenkos Securities plc (NOMAD)

Derrick Lee 00 44 131 220 6939

Neil McDonald

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKAPAEDXEFF
Date   Source Headline
20th Aug 20212:00 pmRNSPrice Monitoring Extension
20th Aug 202111:05 amRNSSecond Price Monitoring Extn
20th Aug 202111:00 amRNSPrice Monitoring Extension
20th Aug 20219:05 amRNSSecond Price Monitoring Extn
20th Aug 20219:00 amRNSPrice Monitoring Extension
24th May 20212:06 pmRNSSecond Price Monitoring Extn
24th May 20212:00 pmRNSPrice Monitoring Extension
14th May 202111:05 amRNSSecond Price Monitoring Extn
14th May 202111:00 amRNSPrice Monitoring Extension
13th May 202111:06 amRNSSecond Price Monitoring Extn
13th May 202111:00 amRNSPrice Monitoring Extension
10th May 20219:15 amRNSBlock Admission Six Monthly Return
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:01 pmRNSPrice Monitoring Extension
30th Mar 20219:05 amRNSSecond Price Monitoring Extn
30th Mar 20219:00 amRNSPrice Monitoring Extension
30th Mar 20217:00 amRNSInterim Results
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
16th Mar 20219:05 amRNSSecond Price Monitoring Extn
16th Mar 20219:00 amRNSPrice Monitoring Extension
3rd Mar 20217:00 amRNSHolding(s) in Company
12th Feb 202111:06 amRNSSecond Price Monitoring Extn
12th Feb 202111:00 amRNSPrice Monitoring Extension
27th Jan 20215:50 pmRNSTR-1: Notification of major holdings
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSEtinde Exploitation Authorisation Agreement
11th Jan 20217:00 amRNSAppointment of Chairman
31st Dec 202012:35 pmRNSPrice Monitoring Extension
30th Dec 20204:41 pmRNSSecond Price Monitoring Extn
30th Dec 20204:36 pmRNSPrice Monitoring Extension
17th Dec 20204:36 pmRNSPrice Monitoring Extension
16th Dec 20204:35 pmRNSPrice Monitoring Extension
9th Dec 202011:06 amRNSResult of Annual General Meeting
30th Nov 20204:41 pmRNSSecond Price Monitoring Extn
30th Nov 20204:36 pmRNSPrice Monitoring Extension
26th Nov 20204:41 pmRNSSecond Price Monitoring Extn
26th Nov 20204:35 pmRNSPrice Monitoring Extension
24th Nov 20204:40 pmRNSSecond Price Monitoring Extn
24th Nov 20204:36 pmRNSPrice Monitoring Extension
19th Nov 20204:41 pmRNSSecond Price Monitoring Extn
19th Nov 20204:36 pmRNSPrice Monitoring Extension
16th Nov 20204:36 pmRNSAnnual Financial Report
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
9th Nov 20207:00 amRNSBlock Admission Six Monthly Return
5th Nov 20207:00 amRNSPreliminary Results
2nd Nov 20204:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.